Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors

被引:9
|
作者
Shida, Yoichi [1 ]
Nakazawa, Tsutomu [1 ,2 ]
Matsuda, Ryosuke [1 ]
Morimoto, Takayuki [1 ]
Nishimura, Fumihiko [1 ]
Nakamura, Mitsutoshi [1 ,3 ]
Maeoka, Ryosuke [1 ]
Yamada, Shuichi [1 ]
Nakagawa, Ichiro [1 ]
Park, Young-Soo [1 ]
Yasukawa, Motoaki [4 ,5 ]
Tojo, Takashi [4 ,6 ]
Tsujimura, Takahiro [3 ]
Nakase, Hiroyuki [1 ]
机构
[1] Nara Med Univ, Dept Neurosurg, Kashihara, Nara 6348521, Japan
[2] Grandsoul Res Inst Immunol Inc, Uda, Nara 6332221, Japan
[3] Clin Grandsoul Nara, Uda, Nara 6332221, Japan
[4] Nara Med Univ, Dept Thorac Surg, Kashihara, Nara 6348521, Japan
[5] Osaka Kaisei Hosp, Dept Surg, Yodogawa, Osaka 5320003, Japan
[6] Saiseikai Chuwa Hosp, Dept Thorac Surg, Sakurai, Nara 6330054, Japan
关键词
PD-1; PD-L1; NK cell; glioblastoma; NEWLY-DIAGNOSED GLIOBLASTOMA; DELTA-T CELLS; ADJUVANT TEMOZOLOMIDE; PD-L1; EXPRESSION; NK CELLS; IMMUNOTHERAPY; THERAPY; RADIOTHERAPY; CONCOMITANT; PATTERNS;
D O I
10.3390/ijms22189975
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glioblastoma (GBM) is the leading malignant intracranial tumor and is associated with a poor prognosis. Highly purified, activated natural killer (NK) cells, designated as genuine induced NK cells (GiNKs), represent a promising immunotherapy for GBM. We evaluated the anti-tumor effect of GiNKs in association with the programmed death 1(PD-1)/PD-ligand 1 (PD-L1) immune checkpoint pathway. We determined the level of PD-1 expression, a receptor known to down-regulate the immune response against malignancy, on GiNKs. PD-L1 expression on glioma cell lines (GBM-like cell line U87MG, and GBM cell line T98G) was also determined. To evaluate the anti-tumor activity of GiNKs in vivo, we used a xenograft model of subcutaneously implanted U87MG cells in immunocompromised NOG mice. The GiNKs expressed very low levels of PD-1. Although PD-L1 was expressed on U87MG and T98G cells, the expression levels were highly variable. Our xenograft model revealed that the retro-orbital administration of GiNKs and interleukin-2 (IL-2) prolonged the survival of NOG mice bearing subcutaneous U87MG-derived tumors. PD-1 blocking antibodies did not have an additive effect with GiNKs for prolonging survival. GiNKs may represent a promising cell-based immunotherapy for patients with GBM and are minimally affected by the PD-1/PD-L1 immune evasion axis in GBM.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study
    Tahereh Rostami
    Mohammad Ahmadvand
    Morteza Azari
    Amir Kasaeian
    Bahram Chahardouli
    Mohammad Reza Shemshadi Nia
    Mojtaba Azari
    Mohammad Reza Rostami
    Ramin Ahangar-Sirous
    Azadeh Kiumarsi
    Ghasem Janbabai
    Cancer Immunology, Immunotherapy, 74 (5)
  • [22] The Use of Ex Vivo Expanded Human Invariant Natural Killer T Cells as a Novel Cell Therapy to Modulate Graft-Versus-Host-Disease
    Im, Jin Seon
    He, Hong
    Rezvani, Katy
    Shpall, Elizabeth J.
    Ma, Qing
    Molldrem, Jeffrey
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S399 - S399
  • [23] Higher-Dose Donor Derived Ex Vivo Expanded Natural Killer Cell Infusion Prior to Haploidentical Stem Cell Transplantation on Acute Myeloid Leukemia: Efficacy and Safety
    Wang, Weida
    Liang, Yang
    Song, Yuanbin
    Huang, Hanying
    Wu, Bingyi
    BLOOD, 2022, 140 : 12713 - 12713
  • [24] Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
    Chu, Yaya
    Nayyar, Gaurav
    Jiang, Susiyan
    Rosenblum, Jeremy M.
    Soon-Shiong, Patrick
    Safrit, Jeffrey T.
    Lee, Dean A.
    Cairo, Mitchell S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 8 (07)
  • [25] A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors
    Otegbeye, Folashade
    Cooper, Brenda
    Caimi, Paolo
    Zamborsky, Kayla
    Reese-Koc, Jane
    Hillian, Antoinette
    Hernandez-Collazo, Yeritza
    Lee, Grace
    Boughan, Kirsten
    Tomlinson, Benjamin
    Gallogly, Molly
    Metheny, Leland
    Bajor, David
    Selfridge, Jennifer
    Saltzman, Joel
    Lazarus, Hillard
    de Lima, Marcos
    Wald, David
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (05): : 250.e1 - 250.e8
  • [26] Spontaneous In Vivo Differentiation of Embryonic Stem Cell-Derived Pancreatic Endoderm-Like Cells Corrects Hyperglycemia in Diabetic Mice
    Raikwar, Sudhanshu P.
    Zavazava, Nicholas
    TRANSPLANTATION, 2011, 91 (01) : 11 - 20
  • [27] Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line
    Shman, Tatsiana V.
    Vashkevich, Katsiaryna P.
    Migas, Alexandr A.
    Matveyenka, Mikhail A.
    Lasiukov, Yauheni A.
    Mukhametshyna, Nastassia S.
    Horbach, Katsiaryna I.
    Aleinikova, Olga V.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2551 - 2560
  • [28] Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line
    Tatsiana V. Shman
    Katsiaryna P. Vashkevich
    Alexandr A. Migas
    Mikhail A. Matveyenka
    Yauheni A. Lasiukov
    Nastassia S. Mukhametshyna
    Katsiaryna I. Horbach
    Olga V. Aleinikova
    Clinical and Experimental Medicine, 2023, 23 : 2551 - 2560
  • [29] Engineered Induced Pluripotent Stem Cell-Derived Natural Killer Cells Reactively Co-Target TIGIT and CD73 in the Glioblastoma Tumor Microenvironment
    Lupo, Kyle B.
    Matosevic, Sandro
    MOLECULAR THERAPY, 2022, 30 (04) : 397 - 397
  • [30] Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer
    Shevtsov, Maxim
    Pitkin, Emil
    Ischenko, Alexander
    Stangl, Stefan
    Khachatryan, William
    Galibin, Oleg
    Edmond, Stanley
    Lobinger, Dominik
    Multhoff, Gabriele
    FRONTIERS IN IMMUNOLOGY, 2019, 10